CFR Subpart I

CFR Subpart I
in effect

21 C.F.R. § 606.160 Records.

(a)(1) Records shall be maintained concurrently with the performance of each significant step in the collection, processing, compatibility testing, storage and distribution of each unit of blood and blood components so that all steps can be clearly traced. All records shall be legible and indelible, and shall identify the person performing the work, include dates of the various entries, show test results as well as the interpretation of the results, show the expiration date assigned to specific products, and be as detailed as necessary to provide a complete history of the work performed. (2) Appropriate records shall be available from which to determine lot numbers of supplies and reagents used for specific lots or units of the final product. (b) Records shall be maintained that include, but are not limited to, the following when applicable: (1) Donor records: (i) Donor selection, including medical interview and examination and where applicable, informed consent. (ii) Permanent and temporary deferrals for health reasons including reason(s) for deferral. (iii) Donor adverse reaction complaints and reports, including results of all investigations and followup. (iv) Therapeutic bleedings, including signed requests from attending physicians, the donor's disease and disposition of units. (v) Immunization, including informed consent, identification of the antigen, dosage and route of administration. (vi) Blood collection, including identification of the phlebotomist. (vii) Records to relate the donor with the unit number of each previous donation from that donor. (viii) Records concerning the following activities performed under §§ 610.46 and 610.47 of this chapter: Quarantine; consignee notification; testing; notification of a transfusion recipient, the recipient's physician of record, or the recipient's legal representative; and disposition. (ix) The donor's postal address provided at the time of donation where the donor may be contacted within 8 weeks after donation. (x) Records of notification of donors deferred or determined not to be eligible for donation, including appropriate followup if the initial attempt at notification fails, performed under § 630.40 of this chapter. (xi) Records of notification of the referring physician of a deferred autologous donor, including appropriate followup if the initial attempt at notification fails, performed under § 630.40 of this chapter. (2) Processing records: (i) Blood processing, including results and interpretation of all tests and retests. (ii) Component preparation, including all relevant dates and times. (iii) Separation and pooling of recovered plasma. (iv) Centrifugation and pooling of source plasma. (v) Labeling, including initials of the person(s) performing the procedure. (3) Storage and distribution records: (i) Distribution and disposition, as appropriate, of blood and blood products. (ii) Visual inspection of whole blood and red blood cells during storage and immediately before distribution. (iii) Storage temperature, including initialed temperature recorder charts. (iv) Reissue, including records of proper temperature maintenance. (v) Emergency release of blood, including signature of requesting physician obtained before or after release. (4) Compatibility test records: (i) Results of all compatibility tests, including crossmatching, testing of patient samples, antibody screening and identification. (ii) Results of confirmatory testing. (5) Quality control records: (i) Calibration and standardization of equipment. (ii) Performance checks of equipment and reagents. (iii) Periodic check on sterile technique. (iv) Periodic tests of capacity of shipping containers to maintain proper temperature in transit. (v) Proficiency test results. (6) Transfusion reaction reports and complaints, including records of investigations and followup. (7) General records: (i) Sterilization of supplies and reagents prepared within the facility, including date, time interval, temperature and mode. (ii) Responsible personnel. (iii) Biological product deviations. (iv) Maintenance records for equipment and general physical plant. (v) Supplies and reagents, including name of manufacturer or supplier, lot numbers, expiration date and date of receipt. (vi) Disposition of rejected supplies and reagents used in the collection, processing and compatibility testing of blood and blood components. (c) A donor number shall be assigned to each accepted donor, which relates the unit of blood collected to that donor, to his medical record, to any component or blood product from that donor's unit of blood, and to all records describing the history and ultimate disposition of these products. (d) Records shall be retained for such interval beyond the expiration date for the blood or blood component as necessary to facilitate the reporting of any unfavorable clinical reactions. You must retain individual product records no less than 10 years after the records of processing are completed or 6 months after the latest expiration date for the individual product, whichever is the later date. When there is no expiration date, records shall be retained indefinitely. (e) Records of deferred donors. (1) Establishments must maintain at each location a record of all donors found to be ineligible or deferred at that location so that blood and blood components from an ineligible donor are not collected and/or released while the donor is ineligible or deferred; and (2) Establishments must maintain at all locations operating under the same license or under common management a cumulative record of donors deferred from donation under § 610.41 of this chapter because their donation tested reactive under § 610.40(a)(1) of this chapter for evidence of infection due to HIV, HBV, or HCV. In addition, establishments other than Source Plasma establishments must include in this cumulative record donors deferred from donation under § 610.41 of this chapter because their donation tested reactive under § 610.40(a)(2) of this chapter for evidence of infection due to HTLV or Chagas disease. (3) The cumulative record described in paragraph (e)(2) of this section must be updated at least monthly to add donors newly deferred under § 610.41 of this chapter due to reactive tests for evidence of infection due to HIV, HBV, or HCV, and, if applicable, HTLV or Chagas disease. (4) Establishments must revise the cumulative record described in paragraph (e)(2) of this section to remove donors who have been requalified under § 610.41(b) of this chapter.

21 C.F.R. § 606.165 Distribution and receipt; procedures and records.

(a) Distribution and receipt procedures shall include a system by which the distribution or receipt of each unit can be readily determined to facilitate its recall, if necessary. (b) Distribution records shall contain information to readily facilitate the identification of the name and address of the consignee, the date and quantity delivered, the lot number of the unit(s), the date of expiration or the date of collection, whichever is applicable, or for crossmatched blood and blood components, the name of the recipient. (c) Receipt records shall contain the name and address of the collecting facility, date received, donor or lot number assigned by the collecting facility and the date of expiration or the date of collection, whichever is applicable.

21 C.F.R. § 606.170 Adverse reaction file.

(a) Records shall be maintained of any reports of complaints of adverse reactions regarding each unit of blood or blood product arising as a result of blood collection or transfusion. A thorough investigation of each reported adverse reaction shall be made. A written report of the investigation of adverse reactions, including conclusions and followup, shall be prepared and maintained as part of the record for that lot or unit of final product by the collecting or transfusing facility. When it is determined that the product was at fault in causing a transfusion reaction, copies of all such written reports shall be forwarded to and maintained by the manufacturer or collecting facility. (b) When a complication of blood collection or transfusion is confirmed to be fatal, the Director, Office of Compliance and Biologics Quality, CBER, must be notified by telephone, facsimile, express mail, or electronically transmitted mail as soon as possible. A written report of the investigation must be submitted to the Director, Office of Compliance and Biologics Quality, CBER, by mail, facsimile, or electronically transmitted mail (for mailing address, see § 600.2(a) of this chapter), within 7 days after the fatality by the collecting facility in the event of a donor reaction, or by the facility that performed the compatibility tests in the event of a transfusion reaction.

21 C.F.R. § 606.171 Reporting of product deviations by licensed manufacturers, unlicensed registered blood establishments, and transfusion services.

(a) Who must report under this section? You, a licensed manufacturer of blood and blood components, including Source Plasma; an unlicensed registered blood establishment; or a transfusion service who had control over the product when the deviation occurred, must report under this section. If you arrange for another person to perform a manufacturing, holding, or distribution step, while the product is in your control, that step is performed under your control. You must establish, maintain, and follow a procedure for receiving information from that person on all deviations, complaints, and adverse events concerning the affected product. (b) What do I report under this section? You must report any event, and information relevant to the event, associated with the manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution, of both licensed and unlicensed blood or blood components, including Source Plasma, if that event meets all the following criteria: (1) Either: (i) Represents a deviation from current good manufacturing practice, applicable regulations, applicable standards, or established specifications that may affect the safety, purity, or potency of that product; or (ii) Represents an unexpected or unforeseeable event that may affect the safety, purity, or potency of that product; and (2) Occurs in your facility or another facility under contract with you; and (3) Involves distributed blood or blood components. (c) When do I report under this section? You should report a biological product deviation as soon as possible but you must report at a date not to exceed 45-calendar days from the date you, your agent, or another person who performs a manufacturing, holding, or distribution step under your control, acquire information reasonably suggesting that a reportable event has occurred. (d) How do I report under this section? You must report on Form FDA-3486. (e) Where do I report under this section? You must send the completed Form FDA 3486 to the Center for Biologics Evaluation and Research (CBER), either in paper or electronic format. (1) If you make a paper filing, send the completed form to the CBER Document Control Center (see mailing address in § 600.2(a) of this chapter), and identify on the envelope that a BPDR (biological product deviation report) is enclosed; or (2) If you make an electronic filing, send the completed Form FDA3486 electronically using CBER's electronic Web-based application. (f) How does this regulation affect other FDA regulations? This part supplements and does not supersede other provisions of the regulations in this chapter. All biological product deviations, whether or not they are required to be reported under this section, should be investigated in accordance with the applicable provisions of parts 211, 606, and 820 of this chapter.

Starting a business? Corpus forms LLCs in all 50 states and DC.